Benzinga | Dec 14, 2020 07:58AM EST

BMO Capital Downgrades Alexion Pharmaceuticals to Market Perform, Raises Price Target to $175

BMO Capital analyst Matthew Luchini downgrades Alexion Pharmaceuticals (NASDAQ:ALXN) from Outperform to Market Perform and raises the price target from $152 to $175.